Nurix Therapeutics, Inc. (NRIX) Reports In-Line Q3 EPS

Nurix Therapeutics, Inc. (NASDAQ: NRIX) reported Q3 EPS of ($0.67), in-line with the analyst estimate of ($0.67). Revenue for the quarter came in at $12.6 million versus the consensus estimate of $14.98 million.

For earnings history and earnings-related data on Nurix Therapeutics, Inc. (NRIX) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Shein targets $26-27 billion valuation in Hong Kong IPO - report
• Cohen & Steers and DLC acquire Virginia grocery shopping center